Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Tom Martin, Paul G. Richardson, Thierry Façon, Philippe Moreau, Aurore Perrot, Ivan Špıčka, Kamlesh Bisht, Marlène Inchauspé, France Casca, Sandrine Macé, Helgi van de Velde, Kenshi Suzuki
Abstract
Not available.
Topics & Concepts
Multiple myelomaMedicineInternal medicineRefractory (planetary science)OncologyFamily medicinePsychologyBiologyAstrobiologyMultiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisChronic Lymphocytic Leukemia Research